We previously investigated CPVT-associated CaM variants and showed that CaM-N53I did not affect the kinase activity of CaMKIIδ, whereas CaM-A102V significantly increased substrate phosphorylation levels by ∼60% (79). The gene discussed is CALM3; the disease is catecholaminergic polymorphic ventricular tachycardia.